Sulodexide

ApprovedSmall molecule

KKeryx Biopharmaceuticals

Sulodexide is one of 295 small molecule programs targeting Albuminuria. It is currently in Approved.

Indications

Total Trials

Active Trials

294

Competitors

Pipeline

Status by Indication[3][1]

Indication

AlbuminuriaActive, not recruiting

Venous ThromboembolismActive, not recruiting

Diabetic NephropathyActive, not recruiting

TinnitusActive, not recruiting

Dense Deposit DiseaseActive, not recruiting

Adverse EffectActive, not recruiting

PsoriasisActive, not recruiting

COVID-19Active, not recruiting

Diabetic RetinopathyActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

AlbuminuriaApproved

Active, not recruiting

Venous ThromboembolismPhase 3

Active, not recruiting

Diabetic NephropathyPhase 3

Active, not recruiting

TinnitusPhase 2

Active, not recruiting

Dense Deposit DiseasePhase 1

Active, not recruiting

Adverse EffectPreclinical

Active, not recruiting

PsoriasisPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Diabetic RetinopathyPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Sulodexide

KKeryx Biopharmaceuticals

Approved

3 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Singulair

AstraZeneca

Preclinical

1 7

Stivarga

Bayer

Preclinical

1 8

Aimovig

Amgen

Preclinical

1 9

Aldactone

Pfizer

Preclinical

1 10

Nexavar

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Venous Thromboembolism

NCT04257487

Clinical

Trials by Indication[1]

COVID-193 trials

Endothelial Protection in Convalescent COVID-19 Patients

Terminated·PPirogov Russian National Research Medical University·Phase 4·NCT05252923·2 enrolled

Endothelial Protection in Post COVID-19 Patients With Sulodexide

Completed·CCentro Medico del Noroeste·Phase 3·NCT05371925·206 enrolled

Suloexide in the Treatment of Early Stages of COVID-19

Completed·CClinedem·Phase 2/3·NCT04483830·243 enrolled

Diabetic Nephropathy2 trials

Effect of Sulodexide in Overt Diabetic Nephropathy

Terminated·KKeryx Biopharmaceuticals·Phase 4·NCT00130312·968 enrolled

Effect of Sulodexide in Early Diabetic Nephropathy

Completed·KKeryx Biopharmaceuticals·Phase 3·NCT00130208·1,056 enrolled

Chronic Kidney Disease1 trial

The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease

Unknown status·CCorbridge Group Philippines, Inc.·Phase 3·NCT01000545·1,508 enrolled

Tinnitus1 trial

Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus

Completed·SSt Joseph University, Beirut, Lebanon·Phase 2·NCT02737670·126 enrolled

Psoriasis1 trial

Sulodexide in Controlling the Recurrence of Psoriasis

Enrolling by invitation·XXijing Hospital·Phase 3·NCT06982196·160 enrolled

8 more indications

Adverse Effect1 trial

The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

Unknown status·—·N/A·NCT05654233·120 enrolled

Diabetic Retinopathy1 trial

Diabetic Retinopathy Sulodexide Study

Completed·—·Phase 2·NCT01295775·127 enrolled

Dense Deposit Disease1 trial

Sulodexide Treatment in Patients With Dense Deposit Disease

Withdrawn·UUniversity of Iowa·Phase 1·NCT00583427

Prospective1 trial

Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide

Terminated·BBama GeVe, S.L.U.·Phase 4·NCT02512601·13 enrolled

Endothelial Function1 trial

Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone

Unknown status·AAlfa Wassermann Tunisia·Phase 3·NCT03370705·156 enrolled

Albuminuria1 trial

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Withdrawn·SSteno Diabetes Center Copenhagen·Phase 4·NCT03504566

Venous Thromboembolism1 trial

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

Recruiting·AArianna Anticoagulazione Foundation·Phase 3·NCT04257487·1,455 enrolled

Unspecified1 trial

Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong

Terminated·KKeryx Biopharmaceuticals·Phase 3·NCT00462202·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Sulodexide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulodexide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulodexide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Keryx Biopharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: KKeryx Biopharmaceuticals

Sulodexide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

COVID-193 trials

Diabetic Nephropathy2 trials

Chronic Kidney Disease1 trial

Tinnitus1 trial

Psoriasis1 trial

Adverse Effect1 trial

Diabetic Retinopathy1 trial

Dense Deposit Disease1 trial

Prospective1 trial

Endothelial Function1 trial

Albuminuria1 trial

Venous Thromboembolism1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News